Adtec Healthcare's new project with Hull York Medical School testing gas plasma on Osteomyelitis bone infections.

We are excited to announce the study “Gas Plasma for the Prevention and Management of Osteomyelitis Biofilms” has now begun at the Hull York Medical School. The study led by Dr Angela Oates and funded by the National Biofilms Innovation Centre will seek to test the efficacy of our gas plasma system on osteomyelitis bone infections using our PlasmaTact device. This project will develop a novel laboratory testing model to evaluate and optimise plasma treatment for osteomyelitis biofilm infections.

We have already demonstrated that our gas plasma medical device, the Adtec SteriPlas, has proven antibacterial efficacy and accelerated healing in problematic and non-healing wounds with strong evidence collected from our extensive library of clinical trials and publications. This includes diabetic foot ulcers which are often complicated by biofilm. Over the course of its existence it has shown that no side effects have been reported which offers patients a safe and reliable treatment option. It has also shown that a 2-minute treatment time is sufficient to achieve exceptional results and that it is also a broad spectrum antibacterial with the ability to kill a wide range of Gram-negative and Gram-positive bacterial superinfections.

The PlasmaTact utilizes the same gas plasma technology from the Adtec SteriPlas. The main difference between the two devices is that the PlasmaTact offers a smaller handheld style treatment area of 1cm2 (vs 12cm2 with the SteriPlas) and offers users the ability to change the power output settings (vs the fixed settings with the SteriPlas).

Osteomyelitis (OM) is biofilm infection of the bone and is a common and costly complication in diabetic foot ulcer (DFU) patients often resulting in amputations. Long-term antimicrobial therapy is widely used as a primary treatment for OM or as an adjunct to surgical approaches however, there is a failure rate of up to 35% and an associated increasing prevalence of antimicrobial resistance. There is an urgent clinical need to develop alternative non-antimicrobial approaches to treat infections, and currently there is a lack of credible alternatives in the market for the treatment of OM.

Evaluating the efficacy of gas plasma in OM represents unique challenges as both the biofilm growth and physical characteristics of OM bone will affect the delivery and activity of the plasma. In vitro biofilm model systems offer a means by which rapid, costs effective and standardised evaluation of anti-biofilm treatments can be undertaken.

The PATROL project is a new and exciting collaborative project between Adtec Healthcare and Dr Angela Oates of the University of Hull Wound Healing Group which is supported by NBIC PoC Award. The overall aim of this project is to develop an osteomyelitis biofilm infection model to support the optimisation and evaluation of a cold plasma technology for the management and prevention of OM.

This collaborative project represents the first phase of the novel utilisation of Adtec SteriPlas to treat OM or as an adjunct current therapy. Successful translation of this technology to treat OM will reduce antimicrobial usage and associated OM amputations, reducing NHS costs and ultimately improving patient outcomes.

#osteomyelitis #biofilm #boneinfection #infection #antimicrobial #antimicrobialresistance #amputation #plasma #gasplasma #coldplasma #kaltesplasma #NBIC #universityofhull #podiatry #diabeticfootulcer #diabeticfoot #diabetes #hullyorkmedicalschool


Adtec Healthcare confirms attendance for 3rd conference in 2020

Adtec Healthcare looks forward to exhibiting at the Diabetic Foot Study Group (DFSG) conference in Bratislava, Slovakia between 18-20 September 2020.

You can find us at booth 13 in the exhibition hall where our staff will be ready to welcome you. We will also have our flagship medical device, the Adtec SteriPlas, live on demonstration to show you how easy it is to treat diabetic foot ulcers.

#plasma #coldplasma #kaltesplasma #gasplasma #DFSG #DFSG2020 #diabeticfootulcer #wound #woundcare #woundhealing #wundkongress #wund #medicaldevice #DFSG #DFSG2020


Adtec Healthcare exhibiting at two leading wound conferences this year

Adtec Healthcare looks forward to exhibit at the European Wound Management Association (EWMA) conference and The Malvern Diabetic Foot Conference in May 2020. As the two conferences will be running on the same dates (13th-15th May ’20), we will have teams exhibiting at both conferences so we can meet with you at whichever conference you attend.

We will have our medical device live on display at both exhibitions and look forward to inviting you to our booth to give a demonstration on its ease of use to achieve remarkable results.

#EWMA #EWMA2020 #MalvernDFU #Malvern2020 #wound #wundkongress #coldplasma #kaltesplasma #gasplasma #plasma #exhibition #woundcare #surgicalsiteinfection #preventSSI #SSIprevention


Randomised Controlled Clinical Trials of Adtec SteriPlas/MicroPlaSter Plasma Treatment of Wounds and Dermatological conditions over a 14 year period.

Adtec Healthcare’s plasma technology has been tested in 7 randomised controlled clinical trials with proven clinical efficacy and safety. The first participant in an RCT with our plasma technology was on 24th October 2005 - This was also the first RCT worldwide to investigate the clinical efficacy of cold plasma. We continue to be actively involved in RCTs and clinical studies with SteriPlas to produce strong clinical evidence. 

The results of these trials include wound size reduction, bigger reduction of bacterial load compared to antibiotics, treatment of AK lesions and reduction of pain with no adverse events reported.

1. ACTICAP - A prospective, randomised, monocentric, rater blinded study evaluating the change of the cutaneous microbiome in correlation to the efficacy of cold atmospheric plasma treatment in comparison to diclofenac 3% in 2.5% hyaluronic acid (Solaraze 3% Gel®) in patients with actinic keratoses
University Hospital Essen, Germany
Status – Trial completed 2019 and publication planned 2020

2. Prospective, Randomised and Placebo Controlled Clinical Trial (RCT) for the validation of treatment of chronic wounds with cold atmospheric plasma (CAP)
University Hospital Essen, Germany
Status – Trial completed 2018 and publication planned 2020

3. A randomised controlled trial to evaluate the efficacy of non-thermal gas plasma (NTGP) on sub-clinical wound infection (biofilm) in patients with diabetic foot ulcers compared to those treated with standard of care dressings
Salford Royal Foundation Trust, UK
Leeds TeachingHospital, UK
Status – Trial ongoing

4. Low temperature argon plasma for in vivo sterilization of chronic wounds
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed 2013 and published
Successful and Safe Use of 2 Min Cold Atmospheric Argon Plasma in Chronic Wounds: Results of A Randomized Controlled Trial. Isbary ,British Journal of Dermatology, 2012.
A first prospective randomized controlled trial to decrease bacterial load using cold atmospheric argon plasma on chronic wounds in patients, Isbary ,British Journal of Dermatology, 2010

5. Randomised placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites
University Hospital Regensburg Germany
Status – Trial completed and published
Randomized placebo-controlled human pilot study of cold atmospheric argon plasma on skin graft donor sites. Heinlin Wound Repair Reg 2013

6. Randomised placebo-controlled clinical trial showed cold atmospheric
argon plasma in herpes zoster
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed and published

Randomized placebo-controlled clinical trial showed cold atmospheric argon `plasma relieved acute pain and accelerated healing in herpes zoster, Isbary , Clinical Plasma Medicine,2014,

7. A randomised two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus
Klinikum Schwabing, Germany
University Hospital Regensburg Germany
Status – Trial completed and published
A randomized two-sided placebo-controlled study on the efficacy and safety of atmospheric non-thermal argon plasma for pruritus, Heinlin, J Eur Acad Dermatol Venereol. 2013.


Can two plasma medical devices have the same clinical efficacy?

We have been asked by Health Care Professionals to clarify , “What is the difference between the Adtec SteriPlas (Adtec Healthcare) and other cold plasma technologies such as Plasma Care® ?” or “Can two different plasma technologies have the same clinical efficacy… what’s the difference?”.

The answers to these questions are that there is a significant difference between plasma technologies, and it is therefore not possible to claim a similarity in clinical efficacy as the plasma treatments would be different.

Two devices do not produce the same plasma and it is the composition of the plasma that exerts the effects, beneficial and detrimental. For the importance of patient safety, Adtec Healthcare advises against any other plasma device claiming clinical efficacy from the clinical evidence of the CE approved SteriPlas gas plasma. Adtec’s clinical data should never be used to compare to any other plasma treatment which have not yet been clinically tested.

Atmospheric pressure Plasma has a myriad of potential medical applications from low energy plasmas used for wound healing to higher energy plasmas used to cut bones during an operation or for coagulation. The main differences in all plasma technologies include the different forms of plasmas electrode source designs, types of energy used (RF, DC and microwave) and gas used (argon, helium or nitrogen etc) versus air. The Adtec SteriPlas (MicroPlaSter) plasma technology is based on a microwave powered plasma jet utilising argon gas and the other technology is a DC powered Surface Micro Discharge (SMD) plasma source utilising air as carrier gas. The type of plasma generated corresponds directly to the type of treatment delivered to the patient.  Each type of plasma delivers a specific type of treatment.

During the pre-clinical trials and studies, Max Planck had conducted a study illustrating the noticeable differences of our argon gas microwave plasma treatment vs the surface micro-discharge (SMD) ‘Air plasma’ treatment developed at MPI. In this study, clear distinctions could be observed such as argon gas plasma treatment included predictable, safe and low dosages of reactive species whereas air-based plasmas would deliver significantly higher concentrations (over 37 times more than argon microwave plasma).  Air Plasma has much higher levels of NOx and Ozone than argon gas plasma and needs to be tested not only clinically but also safety for the operator. It is essential to verify the product safety and clinical safety of these higher levels of NOx. The air-based plasmas are also generally dependent on the surrounding environment; temperature and humidity will affect the way the plasmas are generated and therefore difficult to deliver the same treatment each time the plasma is generated.

Adtec Plasma Technology has been at the forefront for the development of plasma products for over 30 years, proudly placing us as one of the leaders in the semiconductor and RF plasma market. Adtec has also developed other plasma technologies (gas and air) for remote plasma, gas abatement and surface treatment applications.

In 2002, we designed our first cold plasma technology showing painless effect on contact with human skin. This revolutionised the way how we are used to dealing with plasmas – typically sought as too hot to touch but now redesigned to be colder and harmless on contact with skin. In 2004, our research results were presented at a plasma conference showing distinctive microbial load reduction was possible when bacteria were exposed to our gas plasma.

Later in 2004, Adtec introduced this plasma technology to the Max Planck Institute for Extraterrestrial Physics leading to a collaboration in plasma medicine. The Adtec plasma source was adapted to a wide area plasma source in collaboration with MPI.  This plasma source of the medical device is a shared patent with Adtec and MPI (as seen in the image below). This plasma source is one of the critical components used in the SteriPlas and MicroPlaSter. Adtec solely and exclusively designed and developed the medical device prototypes and products including customized components, electrical, mechanical and software program satisfying the strict standards of European medical device regulations.

We are grateful to the plasma medicine team at Max Planck for having an interest in our plasma technology system, for carrying out extensive scientific research and for managing the clinical trials using the Adtec MicroPlaSter. These clinical trials placed our medical device as the first worldwide to be used in clinical trials on wounds, paving a new treatment programme that would later be adopted by other companies with an interest to develop gas plasma medical devices.  The extensive research and clinical testing assure us of the safety of the product and the technology.

The new European MDR regulations coming into force next year also require all companies to produce proper clinical evidence to support their product claims. We do emphasize the importance of proper pre-clinical and clinical testing of all types of plasma technologies in order to be assured of the product and clinical safety. Adtec Healthcare do encourage and support plasma companies in this industry as our goal is to make gas plasma a recognised treatment option for patients with wounds, surgical site infections and dermatological conditions.


EWMA

We had a great time exhibiting at the EWMA 2019 conference. We would like to congratulate Maurice Moelleken, Dr Heinrich Rotering and Dr Michael Pierides for their brilliant presentations during the conference. Their data showed the strong benefits of using the Adtec SteriPlas on chronic wounds and surgical site infections, offering an alternative to standard treatment therapies that bacteria may pose a resistance to.

The Adtec SteriPlas has proven antibacterial efficacy backed by a wide clinical bibliography and no side effects reported making it safe, painless and effective for the treatment of infected wounds stalled by bacteria.

For more information send us an email to info@adtec.eu.com

Top left (Dr Michael Pierides), top right (Maurice Moelleken), bottom (Dr Heinrich Rotering)

#EWMA #EWMA2019 #antimicrobialresistance #medicaldevice
#gasplasma #coldplasma #kaltesplasma


Poster presentation at the International Symposium on the Diabetic Foot Conference, Hague.

Wednesday 22nd May 2019

A great poster presentation from Dr Aye Aye Thant at the ISDF 2019 conference!

Dr Thant’s presentation demonstrated the benefits of using the Adtec SteriPlas on diabetic foot ulcer patients.

Prior to the use of the Adtec SteriPlas, all patients in their retrospective study suffered from chronic and non-healing foot and leg ulcers with multi resistant bacteria and recalcitrance to antibiotics. All patients had at least 3 courses of intravenous antibiotics for more than 6 weeks prior with poor response.

The Adtec SteriPlas was then introduced as a treatment option. Instantly, positive results could be seen with the infection management for these patients. For example, one patient who was previously considered for an amputation was now improved and risk free. Healthy granulation could be observed with all patients, offering hope and an alternative to antibiotics that would usually be offered.

For more information on the Adtec SteriPlas, visit our website www.adtecplasma.com or send us an email at info@adtec.eu.com


Mr Keith Cutting presents significant results on DFUs in Vienna conference

Mr Keith Cutting presented at The European Conference on Controversies in Diabetic Foot Management conference in Vienna last week. His presentation focused on the benefits of treating complex diabetic foot ulcer patients with the Adtec SteriPlas.

The Adtec SteriPlas has shown promising results leading to healing in problematic and non-healing wounds such as diabetic foot ulcers or surgical site infections. These complex wounds that have shown signs of stalled healing respond well to intervention with the Adtec SteriPlas.

To learn more about our medical device and the benefits it offers to patients with wounds, surgical site infections and dermatological conditions send us an email at info@adtec.eu.com


Deutscher Wundkongress, Bremen 2019

Adtec Healthcare is excited to participate at the DEWU Deutscher Wundkongress in collaboration with other plasma medicine companies next week in Bremen.

https://www.bremer-pflegekongress.de/Teilnehmer_allgemeine_Informationen_w

The plasma medicine companies will introduce the different plasma technologies, product and clinical safety and introduce some of the clinical evidence gathered so far.

This is an exciting opportunity to learn more about gas plasma and we encourage you to attend the session to see the benefits of gas plasma in clinic practice.


Adtec SteriPlas featured in conference presentations for 2019

Adtec Healthcare is excited to attend and support the clinicians presenting at the following conferences for 2019:

The European Conference on Controversies in Diabetic Foot Management conference in Vienna, 2nd – 3rd May 2019 (https://www.diabeticfoot-europe.com/).
Mr Keith Cutting will be conducting an oral presentation on Friday 3
rd May at 14:00. His presentation is titled, “Interim Results from Currently Running Study on the Treatment of Biofilm Infection in Diabetic Foot Ulcers Using Gas Plasma”.

The ISDF 2019 conference in The Netherlands, 22nd – 25th May 2019 (https://diabeticfoot.nl/).
Dr Aye Aye Thant from Kettering General Hospital NHS Foundation Trust will be conducting a poster presentation on “Adtec Cold Plasma Treatment to Assist in Treating Diabetic Foot with Multi Resistant Infection”. This will be presented on Wednesday 22
nd May from 12:10.

The European Wound Management Association (EWMA) conference in Gothenburg, Sweden, 5th – 7th June 2019 (https://ewma.org/ewma-conference/2019/). Presenting clinical evidence at this conference will be:

Maurice Moelleken from the Universitätsklinikum Essen, Germany. Maurice’s oral presentation on “Prospective RCT to validate the interval of cold atmospheric plasma treatment for reduction of bacterial load, wound area and pain in patients with chronic wounds” will be presented on 6th June at 08:50am.

Dr Michael Pierides from Kettering General Hospital NHS Foundation Trust will have an e-poster at the EWMA conference. His poster, “The Gas Plasma Medical Device: A Novel Therapy in Treating Non-Resolving Infected Diabetic Foot and Leg Ulcers” can be viewed throughout the conference.

Dr Heinrich Rotering from the Universitätsklinikum Münster, Germany will be conducting a poster presentation, “Cold Plasma and Advanced Negative Pressure Wound Treatment – Long Term Follow Up of Treated Infected Implants in Cardiac Surgery”, on 6th June between 09:42 – 09:45.

The Surgical Infection Society Europe conference in Dublin, Ireland, 26th – 28th June (http://sis-e.org/2019/).
Dr Heinrich Rotering will have a poster at this conference. His poster, “Infection of Cardiovascular Implantable Electronic Devices (CIED) – New Approach with Cold Atmospheric Plasma (CAP)” can be viewed throughout the conference.

Adtec Healthcare staff will be present at these conferences to support the presenting speakers and welcome any meetings. Please get in contact with us at info@adtec.eu.com to secure your meeting in advance.